Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
Harmony Biosciences (Nasdaq: HRMY) will present encore data from its investigation of EPX-100 (clemizole hydrochloride) at the 16th European Epilepsy Congress, held September 5-9 in Athens, Greece. EPX-100 is being studied in the currently enrolling ARGUS trial for Dravet syndrome and LIGHTHOUSE trial for Lennox-Gastaut syndrome; the two posters cover preliminary open-label extension results from ARGUS and a drug-drug interaction study of EPX-100 with CYP enzyme probe substrates.
Key figures
- Drug Name
- EPX-100 (clemizole hydrochloride)
- Phase Of Trial
- open-label extension phase (ARGUS study); LIGHTHOUSE currently enrolling
- Congress
- 16th European Epilepsy Congress, September 5-9, Athens, Greece
- Poster numbers
- ["P0342","P0331"]
- Dravet incidence
- 1:15,700
- Lgs us patient population
- 48000
- Scn1a lof share of dravet cases
- 85%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.